Single cell transcriptomics of the tumor immune microenvironment from checkpoint blockade-treated and/or TBK1 inhibitor-treated B16-OVA tumors

Recent studies have demonstrated critical roles for TBK1 in regulation of activity of numerous immune cell types, including T cells, B cells, dendritic cells, and macrophages. To examine the effect of TBK1 inhibition on the tumor immune microenvironment, we performed scRNA-seq on CD45+ cells from B16-OVA tumors from mice treated with anti-PD-1, TBK1i, or anti-PD-1 plus TBK1i, compared to isotype control (IgG). Overall design: B16-OVA tumors were treated with either anti-PD1 monoclonoal antibody or isotype IgG by IP injection on days 1, 2, 4, 6, 8, and 11 post tumor challenge and either TBK1 inhibitor or vehicle by oral gavage daily for 18 days post tumor challenge. CD45+ cells were isolated from B16-OVA tumors and analyzed using scRNA-seq (10X Genomics, 3'v2 chemistry).